Arachk de Gorski1, Morgan Rouprêt2, Benoit Peyronnet1, Chloé Le Cossec3, Benjamin Granger3, Eva Comperat4, Olivier Cussenot5, Raphaële Renard-Penna6, Pierre Mozer7. 1. Academic Department of Urology, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpétrière, Paris, France. 2. Academic Department of Urology, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpétrière, Paris, France; GRC5, ONCOTYPE-Uro, Institut Universitaire de Cancérologie, Université Pierre et Marie Curie-Université Paris 06, Paris, France. Electronic address: mroupret@gmail.com. 3. Academic Department of Biostatistics, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpétrière, Paris, France. 4. Academic Department of Pathology, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpétrière, Paris, France. 5. Academic Department of Urology, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpétrière, Paris, France; GRC5, ONCOTYPE-Uro, Institut Universitaire de Cancérologie, Université Pierre et Marie Curie-Université Paris 06, Paris, France. 6. Academic Department of Radiology, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpétrière, Paris, France. 7. Academic Department of Urology, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpétrière, Paris, France; Institute for Intelligent Systems and Robotics, Université Pierre et Marie Curie-Université Paris 06, Paris, France.
Abstract
PURPOSE: We assessed the accuracy of magnetic resonance imaging/transrectal ultrasound fusion biopsies to diagnose prostate cancer according to gland size. MATERIALS AND METHODS: A prospective study was performed in 232 men with a first round biopsy, multiparametric magnetic resonance imaging with a lesion, a Likert score of 2 or greater and prostate specific antigen less than 10 ng/ml. All men underwent a standard 12-core protocol plus a protocol of 2 or 3 targeted cores. Significant prostate cancer was defined as at least 1 core with a Gleason score of 7 (3 + 4) or 6 with a greater than 4 mm maximal cancer core length. RESULTS: Mean ± SD patient age was 64 ± 6.4 years, mean prostate specific antigen was 6.65 ± 1.8 ng/ml and mean prostate volume was 40 ± 24.3 ml. The overall detection rate of clinically significant prostate cancer was 44%. The detection rate of clinically significant prostate cancer by magnetic resonance imaging-transrectal ultrasound fusion guided biopsy was 77% for prostate glands less than 30 cm(3), and 61%, 47% and 34% for glands 30 to less than 38.5, 38.5 to less than 55 and 55 to 160 cm(3), respectively (p = 0.001). Differences in prostate cancer detection rates between the standard and targeted protocols were not significant for patients with a prostate volume of 40 cm(3) or less (p = 0.8). Conversely 12 patients with a prostate volume greater than 40 cm(3) had clinically significant prostate cancer using the targeted but not the standard protocol and in 3 prostate cancer was detected by the standard but not the targeted protocol (p = 0.04). CONCLUSIONS: Magnetic resonance imaging-transrectal ultrasound fusion biopsies increased the yield of first round prostate biopsies in patients with a prostate volume greater than 40 cm(3).
PURPOSE: We assessed the accuracy of magnetic resonance imaging/transrectal ultrasound fusion biopsies to diagnose prostate cancer according to gland size. MATERIALS AND METHODS: A prospective study was performed in 232 men with a first round biopsy, multiparametric magnetic resonance imaging with a lesion, a Likert score of 2 or greater and prostate specific antigen less than 10 ng/ml. All men underwent a standard 12-core protocol plus a protocol of 2 or 3 targeted cores. Significant prostate cancer was defined as at least 1 core with a Gleason score of 7 (3 + 4) or 6 with a greater than 4 mm maximal cancer core length. RESULTS: Mean ± SD patient age was 64 ± 6.4 years, mean prostate specific antigen was 6.65 ± 1.8 ng/ml and mean prostate volume was 40 ± 24.3 ml. The overall detection rate of clinically significant prostate cancer was 44%. The detection rate of clinically significant prostate cancer by magnetic resonance imaging-transrectal ultrasound fusion guided biopsy was 77% for prostate glands less than 30 cm(3), and 61%, 47% and 34% for glands 30 to less than 38.5, 38.5 to less than 55 and 55 to 160 cm(3), respectively (p = 0.001). Differences in prostate cancer detection rates between the standard and targeted protocols were not significant for patients with a prostate volume of 40 cm(3) or less (p = 0.8). Conversely 12 patients with a prostate volume greater than 40 cm(3) had clinically significant prostate cancer using the targeted but not the standard protocol and in 3 prostate cancer was detected by the standard but not the targeted protocol (p = 0.04). CONCLUSIONS: Magnetic resonance imaging-transrectal ultrasound fusion biopsies increased the yield of first round prostate biopsies in patients with a prostate volume greater than 40 cm(3).
Authors: N Westhoff; F P Siegel; D Hausmann; M Polednik; J von Hardenberg; M S Michel; M Ritter Journal: World J Urol Date: 2016-11-09 Impact factor: 4.226
Authors: Guillermo Lorenzo; Thomas J R Hughes; Pablo Dominguez-Frojan; Alessandro Reali; Hector Gomez Journal: Proc Natl Acad Sci U S A Date: 2019-01-07 Impact factor: 11.205
Authors: Emanuel Darius Cata; Iulia Andras; Teodora Telecan; Attila Tamas-Szora; Radu-Tudor Coman; Dan-Vasile Stanca; Ioan Coman; Nicolae Crisan Journal: Med Pharm Rep Date: 2021-04-29
Authors: Yipeng Hu; Veeru Kasivisvanathan; Lucy A M Simmons; Matthew J Clarkson; Stephen A Thompson; Taimur T Shah; Hashim U Ahmed; Shonit Punwani; David J Hawkes; Mark Emberton; Caroline M Moore; Dean C Barratt Journal: IEEE Trans Biomed Eng Date: 2016-06-21 Impact factor: 4.538
Authors: Katherine G Holder; Bernardo Galvan; Andrew S Knight; Freedom Ha; Reagan Collins; Preston E Weaver; Luis Brandi; Werner T de Riese Journal: Investig Clin Urol Date: 2021-05-31